[go: up one dir, main page]

LU92200I1 - Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables - Google Patents

Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Info

Publication number
LU92200I1
LU92200I1 LU92200C LU92200C LU92200I1 LU 92200 I1 LU92200 I1 LU 92200I1 LU 92200 C LU92200 C LU 92200C LU 92200 C LU92200 C LU 92200C LU 92200 I1 LU92200 I1 LU 92200I1
Authority
LU
Luxembourg
Prior art keywords
linaclotide
protected
pharmaceutically acceptable
acceptable salts
including pharmaceutically
Prior art date
Application number
LU92200C
Other languages
English (en)
Other versions
LU92200I2 (fr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32854294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92200(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LU92200I1 publication Critical patent/LU92200I1/fr
Publication of LU92200I2 publication Critical patent/LU92200I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
LU92200C 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables LU92200I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44309803P 2003-01-28 2003-01-28
US47128803P 2003-05-15 2003-05-15
US51946003P 2003-11-12 2003-11-12
PCT/US2004/002390 WO2004069165A2 (fr) 2003-01-28 2004-01-28 Procedes et compositions pour le traitement de troubles gastro-intestinaux

Publications (2)

Publication Number Publication Date
LU92200I1 true LU92200I1 (fr) 2020-06-02
LU92200I2 LU92200I2 (fr) 2024-03-21

Family

ID=32854294

Family Applications (2)

Application Number Title Priority Date Filing Date
LU92200C LU92200I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92201C LU92201I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU92201C LU92201I2 (fr) 2003-01-28 2013-05-22 Linaclotide et toute forme thérapeutique équivalente de celuici, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables

Country Status (28)

Country Link
US (3) US20040266989A1 (fr)
EP (3) EP1911763B1 (fr)
JP (3) JP4584911B2 (fr)
KR (2) KR101227626B1 (fr)
CN (2) CN101787073B (fr)
AT (2) ATE477268T1 (fr)
AU (2) AU2004210161B2 (fr)
BE (1) BE2013C032I2 (fr)
BR (2) BRPI0407071B8 (fr)
CA (1) CA2514507C (fr)
CY (5) CY1110905T1 (fr)
DE (2) DE602004028678D1 (fr)
DK (3) DK1911763T3 (fr)
ES (3) ES2350123T3 (fr)
FR (2) FR13C0030I1 (fr)
HU (1) HUS1300022I1 (fr)
IL (2) IL169863A (fr)
LT (1) LTC1594517I2 (fr)
LU (2) LU92200I2 (fr)
MX (1) MXPA05008097A (fr)
NL (1) NL300593I2 (fr)
NO (3) NO334112B1 (fr)
NZ (2) NZ541595A (fr)
PT (3) PT1911763E (fr)
RU (2) RU2543350C2 (fr)
SG (2) SG168407A1 (fr)
SI (3) SI1911763T1 (fr)
WO (1) WO2004069165A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551760A (zh) 2001-03-29 2004-12-01 ҩ��Э�͹�˾ 用于治疗组织炎症和癌变的鸟苷酸环化酶受体拮抗剂
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
ES2350123T3 (es) * 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
PT1644021E (pt) * 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US20050266028A1 (en) * 2004-05-25 2005-12-01 University Of Georgia Research Foundation, Inc. Compositions and methods for modulating an immune response
WO2006046746A1 (fr) * 2004-10-26 2006-05-04 Ajinomoto Co., Inc. Agent préventif/thérapeutique pour des douleurs viscérales
CA2619650A1 (fr) * 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux
RU2566708C2 (ru) 2005-09-29 2015-10-27 Ипсен Фарма С.А.С. Композиции и способы стимуляции двигательной функции желудочно-кишечного тракта
US20090305993A1 (en) * 2006-02-24 2009-12-10 Ironwood Pharmaceuticals, Inc. Methods and composition for the treatment of gastrointestinal disorders
WO2008106429A2 (fr) * 2007-02-26 2008-09-04 Ironwood Pharmaceuticals, Inc. Procédés et compositions pour le traitement de l'insuffisance cardiaque et d'autres troubles
CA2686414A1 (fr) * 2007-05-04 2008-11-13 Ironwood Pharmaceuticals, Inc. Compositions et procedes de traitement de troubles associes a la retention de sel ou de fluide
CA2688161C (fr) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles
US8969514B2 (en) * 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256156B2 (en) 2008-06-04 2014-09-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (fr) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
WO2010005515A2 (fr) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Procédés d’expression de protéines
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
SMT202000179T1 (it) * 2008-08-15 2020-05-08 Ironwood Pharmaceuticals Inc Formulazioni contenenti linaclotide per la somministrazione orale
MX2011005245A (es) 2008-11-19 2011-06-17 Forest Lab Holdings Ltd Forma cristalina de linaclotida.
ES2608050T3 (es) * 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
WO2010115916A1 (fr) 2009-04-10 2010-10-14 F. Hoffmann-La Roche Ag Procédé d'isolement d'un peptide thérapeutique
MX2012001660A (es) * 2009-08-06 2012-03-26 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para adminstracion oral.
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
KR20120115495A (ko) 2009-11-09 2012-10-18 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
JP5984675B2 (ja) * 2009-12-07 2016-09-06 アイアンウッド ファーマシューティカルズ インコーポレイテッド 胃腸障害の療法
WO2011103311A2 (fr) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Traitements de troubles gastro-intestinaux
WO2011145062A1 (fr) 2010-05-21 2011-11-24 Link Research & Grants Corporation Traitement des acouphènes et de dysfonctions auditives apparentées
US8748575B2 (en) * 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides
JP5921545B2 (ja) 2010-08-11 2016-05-24 アイアンウッド ファーマシューティカルズ インコーポレイテッド リナクロチドの安定な製剤
AU2011302006A1 (en) 2010-09-15 2013-03-07 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase C agonists and methods of use
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2835624A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
WO2012155114A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MD480Z (ro) * 2011-07-07 2012-09-30 Elvira Andon Metoda de tratament al colitei ulceroase nespecifice acute
PL2776055T3 (pl) 2011-08-17 2017-06-30 Ironwood Pharmaceuticals, Inc. Sposoby leczenia zaburzeń żołądkowo-jelitowych
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
WO2014088623A1 (fr) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Compositions de linaclotide
RU2528641C2 (ru) * 2012-08-22 2014-09-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела
CN102875655B (zh) * 2012-09-29 2014-12-17 深圳翰宇药业股份有限公司 一种合成利那洛肽的方法
US20150361139A1 (en) 2013-01-30 2015-12-17 Sandoz Ag Crystalline form of linaclotide
WO2014151206A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
BR112016002789A2 (pt) 2013-08-09 2017-11-21 Ardelyx Inc compostos e métodos para inibir transporte de fosfato
MD3288578T2 (ro) * 2015-05-01 2023-08-31 Ironwood Pharmaceuticals Inc Compoziții pentru curățarea colonului și tratamentul tulburărilor gastrointestinale
EP3430056A4 (fr) * 2016-03-15 2019-11-20 The Regents of the University of California Méthodes et compositions pour traiter et prévenir des maladies associées à l'intégrine alpha 8 beta 1
CN107929718A (zh) * 2017-10-19 2018-04-20 南京星银药业集团有限公司 Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法
CN117599320A (zh) * 2018-10-23 2024-02-27 艾比科生物医学公司 输送装置
CN109467606A (zh) * 2018-11-15 2019-03-15 大连理工大学 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用
WO2020237096A1 (fr) 2019-05-21 2020-11-26 Ardelyx, Inc. Combinaison pour baisser le phosphate sérique chez un patient
RU2712761C1 (ru) * 2019-07-02 2020-01-31 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких
CN111265653B (zh) * 2020-02-09 2023-05-09 华中科技大学同济医学院附属协和医院 心房利钠肽在制备炎症性肠病治疗药物中的应用
US20230035733A1 (en) * 2020-03-26 2023-02-02 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions
EP4469468A1 (fr) 2022-01-28 2024-12-04 Fresenius Kabi iPSUM S.r.l. Procédé de préparation de linaclotide
WO2025207484A1 (fr) * 2024-03-25 2025-10-02 Merveille.Ai Utilisation d'aprépitant et d'un dipeptide cyclique pour le contrôle du poids

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US258687A (en) * 1882-05-30 Grain-binder
US232013A (en) * 1880-09-07 Henry h
US152868A (en) * 1874-07-07 Improvement in type-setting machines
US266989A (en) * 1882-11-07 Automatic fire
US32684A (en) * 1861-07-02 Stump-extkactob
US121961A (en) * 1871-12-19 Improvement in devices for supporting pipe-cores
US73628A (en) * 1868-01-21 mitchell
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6342373B1 (en) * 1983-11-21 2002-01-29 Ucp Gen-Pharma Ag Process for preparing recombinant eglin, protease inhibitor
IT1217123B (it) 1987-02-05 1990-03-14 Rotta Research Lab Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
CH679207A5 (fr) 1989-07-28 1992-01-15 Debiopharm Sa
CA2046830C (fr) 1990-07-19 1999-12-14 Patrick P. Deluca Systeme d'administration des medicaments comprenant une interaction entre une proteine ou une polypeptide et un polymere hydrophobe biodegradable
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
FR2674849B1 (fr) 1991-04-02 1994-12-23 Logeais Labor Jacques Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique.
CH683149A5 (fr) 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5140102A (en) 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5824645A (en) 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
SG50624A1 (en) 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5969097A (en) 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
RU2185393C2 (ru) 1993-01-06 2002-07-20 Кинертон Лимитед Сложный полиэфир и конъюгат на его основе
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5395490A (en) * 1993-05-14 1995-03-07 Intertec, Ltd. Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies
DE69433564T2 (de) * 1993-10-26 2004-12-23 Thomas Jefferson University Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US6054429A (en) 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
EP1336409B1 (fr) 1995-06-27 2007-04-11 Eisai R&D Management Co., Ltd. Compositions et formulations permettant de produire une analgésie et d'inhiber la progression de troubles liés à des douleurs neuropathiques
NZ323387A (en) 1995-11-24 2000-02-28 Smithkline Beecham Spa Quinoline derivatives having neurokinin antagonist activity, preparation and use thereof
GB9524104D0 (en) 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
EP1479708A3 (fr) 1996-04-23 2005-05-25 Ipsen Manufacturing Ireland Limited Polyesters biodégradables et procédé pour leur préparation
US6589750B2 (en) 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
DE59814173D1 (de) 1997-02-28 2008-04-03 Nycomed Gmbh Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
US5893985A (en) 1997-03-14 1999-04-13 The Lincoln Electric Company Plasma arc torch
NZ329807A (en) 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
WO1999014239A1 (fr) 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition pour le traitement du diabete sucre et de l'obesite
US20010006972A1 (en) 1998-04-21 2001-07-05 Stephen A. Williams Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome
IT1304152B1 (it) 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
ES2315753T3 (es) 1999-06-23 2009-04-01 Institut Pasteur Composiciones para el tratamiento de problemas de relaciones interpersonales y trastornos del comportamiento.
HK1043308B (en) 1999-08-18 2004-03-05 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S Sustained release formulation of a peptide
SE9903291D0 (sv) 1999-09-15 1999-09-15 Astra Ab New process
AU7700400A (en) 1999-10-06 2001-05-10 Pharmacia Corporation Uroguanylin as an intestinal cancer inhibiting agent
PT1225897E (pt) 1999-11-01 2005-01-31 John Rhodes Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
WO2001064212A1 (fr) 2000-03-01 2001-09-07 University College London Modulateurs de l'absorption d'endocannabinoide et des recepteurs de vallinoide
ES2235806T3 (es) 2000-12-22 2005-07-16 Institut Pasteur Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr.
EP1365753A2 (fr) 2001-02-02 2003-12-03 Pharmacia Corporation Combinaisons d'uroguanyline et d'inhibiteur de cyclooxygenase-2 pour l'inhibition du cancer de l'intestin
CN1551760A (zh) 2001-03-29 2004-12-01 ҩ��Э�͹�˾ 用于治疗组织炎症和癌变的鸟苷酸环化酶受体拮抗剂
EP1451211A2 (fr) 2001-03-30 2004-09-01 University of Copenhagen Compositions et procedes de modulation de l'activite du recepteur signalant la guanylyl cylclase et de traitement de la maladie de meniere
MY134211A (en) 2001-05-18 2007-11-30 Smithkline Beecham Corp Novel use
WO2002098912A2 (fr) * 2001-06-05 2002-12-12 Yalcin Cetin Utilisation d'un peptide qui active la guanylate-cyclase c pour le traitement de maladies des voies respiratoires par les voies aeriennes, medicament, dispositif d'inhalation et methode de diagnostic
FR2830451B1 (fr) 2001-10-09 2004-04-30 Inst Nat Sante Rech Med Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur
EP1321142A1 (fr) 2001-12-21 2003-06-25 Novartis AG Forme solide pour l'administration orale du Tégaserode
US20040121961A1 (en) 2002-02-04 2004-06-24 Jaime Masferrer Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
AU2003224644A1 (en) 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US20030203055A1 (en) 2002-03-15 2003-10-30 Cypress Bioscience, Inc. Methods of treating visceral pain syndromes
DK1505974T3 (da) 2002-05-17 2009-08-17 Tioga Pharmaceuticals Inc Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
CA2619650A1 (fr) 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux

Also Published As

Publication number Publication date
ATE477268T1 (de) 2010-08-15
CY2013021I1 (el) 2020-05-29
WO2004069165A3 (fr) 2005-03-17
IL221380A0 (en) 2012-09-24
NL300593I2 (nl) 2020-04-15
CY1111058T1 (el) 2015-06-11
DK1911763T3 (da) 2010-11-15
DE602004007105D1 (de) 2007-08-02
IL169863A (en) 2012-10-31
BRPI0407071A (pt) 2006-01-24
ES2387848T3 (es) 2012-10-02
DK2246360T3 (da) 2012-08-13
RU2543350C2 (ru) 2015-02-27
DE602004028678D1 (de) 2010-09-23
AU2009235993A1 (en) 2009-11-26
NO20130460L (no) 2005-10-26
RU2014153593A3 (fr) 2018-08-06
ES2285417T3 (es) 2007-11-16
BE2013C032I2 (fr) 2023-08-22
BRPI0407071B8 (pt) 2021-05-25
US8080526B2 (en) 2011-12-20
US7704947B2 (en) 2010-04-27
CY2013022I1 (el) 2020-05-29
KR20110114682A (ko) 2011-10-19
CA2514507C (fr) 2012-03-20
EP2246360A1 (fr) 2010-11-03
RU2353383C2 (ru) 2009-04-27
BR122018074353B1 (pt) 2019-07-16
SG168407A1 (en) 2011-02-28
KR20050106404A (ko) 2005-11-09
PT1594517E (pt) 2007-07-20
CA2514507A1 (fr) 2004-08-19
AU2004210161B2 (en) 2009-11-26
NO2014013I2 (no) 2014-05-21
CY1110905T1 (el) 2015-06-10
SI1911763T1 (sl) 2010-11-30
AU2004210161A1 (en) 2004-08-19
JP5563384B2 (ja) 2014-07-30
US20040266989A1 (en) 2004-12-30
CN100589839C (zh) 2010-02-17
CN101787073A (zh) 2010-07-28
RU2014153593A (ru) 2016-07-20
CN1795007A (zh) 2006-06-28
JP2010222377A (ja) 2010-10-07
CY2013021I2 (el) 2025-07-04
NO334112B1 (no) 2013-12-09
DE602004007105T2 (de) 2008-02-28
RU2005127058A (ru) 2006-03-10
EP2246360B1 (fr) 2012-06-27
LU92201I2 (fr) 2013-11-22
JP4584911B2 (ja) 2010-11-24
EP1911763A2 (fr) 2008-04-16
WO2004069165A2 (fr) 2004-08-19
NO2014013I1 (no) 2014-06-02
PT1911763E (pt) 2010-11-18
MXPA05008097A (es) 2006-02-08
EP1911763A3 (fr) 2008-06-25
SG192300A1 (en) 2013-08-30
CY1113217T1 (el) 2016-04-13
DK1594517T3 (da) 2007-10-29
EP1594517B1 (fr) 2007-06-20
EP1594517A2 (fr) 2005-11-16
KR101227627B1 (ko) 2013-01-31
NO336768B1 (no) 2015-11-02
ATE365174T1 (de) 2007-07-15
KR101227626B1 (ko) 2013-02-01
NZ570134A (en) 2010-02-26
AU2009235993B2 (en) 2013-07-04
HK1078768A1 (en) 2006-03-24
HUS1300022I1 (hu) 2019-11-28
JP2013116910A (ja) 2013-06-13
SI2246360T1 (sl) 2012-10-30
FR13C0029I2 (fr) 2024-04-19
SI1594517T1 (sl) 2007-10-31
ES2350123T3 (es) 2011-01-18
FR13C0029I1 (fr) 2013-07-05
EP1911763B1 (fr) 2010-08-11
FR13C0030I1 (fr) 2013-07-05
JP2006516631A (ja) 2006-07-06
US20110124583A1 (en) 2011-05-26
PT2246360E (pt) 2012-08-31
NL300593I1 (nl) 2015-10-21
RU2763796C2 (ru) 2022-01-11
NO20053864L (no) 2005-10-26
US20090005534A1 (en) 2009-01-01
LTC1594517I2 (lt) 2020-03-10
CN101787073B (zh) 2013-12-25
BRPI0407071B1 (pt) 2019-02-12
BR122018074353B8 (pt) 2023-05-02
NO20053864D0 (no) 2005-08-18
EP1594517A4 (fr) 2006-03-29
NZ541595A (en) 2008-08-29
LU92200I2 (fr) 2024-03-21
RU2008147983A (ru) 2010-06-10
JP5748791B2 (ja) 2015-07-15

Similar Documents

Publication Publication Date Title
LU92200I1 (fr) Linaclotide et toute forme thérapeutique équivalente de celui-ci, protégé par le brevet de base, y compris des sels pharmaceutiquement acceptables
LU92035I2 (fr) Vemurafenib et les sels pharmaceutiquement acceptables de celui-ci, sous toutes les formes bénéficiant de la protection conférée par le brevet de base
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
LU91960I2 (fr) Télaprévir et chaque forme thérapeutiquement équivalente de celui-ci protégéé par le brevet de base,tels que des sels pharmaceutiquement acceptables et/ou solvates de télaprévir ou solvates de tels sels
DK1575618T3 (da) Dispergerbare farmaceutiske kombinationer
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
EP1495141A4 (fr) Therapeutique du vih
PT1501534E (pt) Formulacoes farmaceuticas
EP1581244A4 (fr) Nouvelles cibles therapeutiques dans la lutte contre le cancer
NO20025357D0 (no) Antranylamider og deres anvendelse som legemidler
SK4325U (sk) Farmaceutická kompozícia s postupným uvoľňovaním
EP1459806A4 (fr) Dechiqueteuse
EP1423141A4 (fr) Vaccin
EP1631259A4 (fr) Nanotechnologie otologique
DK1596870T4 (da) Højdosis-ibandronatformulering
IS7831A (is) Bóluefni
EP1570270A4 (fr) Bioconjugues therapeutiques
PL394604A1 (pl) Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna
NO20044188L (no) Kontrollerte frigjoringsdoseformer
NL1024677A1 (nl) Therapeutische prolinederivaten.
DE60226218D1 (de) Impfstoff gegen pferdeherpesvirus
DE60232445D1 (de) Cetirizin und pseudoephedrin enthaltende tablette
DK1614687T3 (da) Fremgangsmåde til fremstilling af 1,3,4,5-tetrahydro-2H-3-benzazepin-2-onderivater og deres anvendelse ved syntese af ivabradin og farmaceutisk acceptable salte deraf
DE60232976D1 (de) Zerkleinerungsmaschine
NO20051561D0 (no) Vaksine